期刊
INTERNATIONAL JOURNAL OF ONCOLOGY
卷 47, 期 2, 页码 437-445出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/ijo.2015.3055
关键词
breast cancer; multidrug resistance; cancer classifications
类别
资金
- DIUFRO [DI15-2018]
- CONICYT
- FONDECYT [1120006]
- Convenio de Desempeno MINEDUC, Universidad de Tarapaca
Despite continuous advances in the knowledge of breast cancer pathophysiology, this type of neoplasia remains a leading cause of cancer-related death in women worldwide. Carcinogenesis takes a progressive course from somatic mutations, alteration of the DNA repair mechanisms, inhibition of growth suppressors, followed by cell proliferation, tissue invasion and risk of metastasis. Less than 10% of all cancers are hereditary, and in the case of breast cancer only 8%, a phenomenon linked to genetic changes in BRCA1 or BRCA2. All the other cancers can be caused by an infection (15%) or in most cases (75%) the etiology is unknown. Patients with genetic mutations in BRCA1 or BRCA2 have 30-60% likelihood of developing a second primary breast cancer and between 11 and 45% risk of ovarian cancer, HER-2/neu is overexpressed in similar to 30% of human breast tumors and it has a predictive role in chemotherapy and endocrine therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据